<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38909338</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8229</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Infectious diseases and therapy</Title><ISOAbbreviation>Infect Dis Ther</ISOAbbreviation></Journal><ArticleTitle>Perceived Risk for Severe COVID-19 and Oral Antiviral Use Among Antiviral-Eligible US Adults.</ArticleTitle><Pagination><StartPage>1743</StartPage><EndPage>1757</EndPage><MedlinePgn>1743-1757</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-024-01003-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Oral antiviral medications are important tools for preventing severe COVID-19 outcomes. However, their uptake remains low for reasons that are not entirely understood. Our study aimed to assess the association between perceived risk for severe COVID-19 outcomes and oral antiviral use among those who were eligible for treatment based on Centers for Disease Control and Prevention (CDC) guidelines.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We surveyed 4034 non-institutionalized US adults in April 2023, and report findings from 934 antiviral-eligible participants with at least one confirmed SARS-CoV-2 infection since December 1, 2021 and no current long COVID symptoms. Survey weights were used to yield nationally representative estimates. The primary exposure of interest was whether participants perceived themselves to be "at high risk for severe COVID-19." The primary outcome was use of a COVID-19 oral antiviral within 5&#xa0;days of suspected SARS-CoV-2 infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Only 18.5% of antiviral-eligible adults considered themselves to be at high risk for severe COVID-19 and 16.8% and 15.9% took oral antivirals at any time or within 5&#xa0;days of SARS-CoV-2 infection, respectively. In contrast, 79.8% were aware of antiviral treatments for COVID-19. Perceived high-risk status was associated with being more likely to be aware (adjusted prevalence ratio [aPR]: 1.11 [95% confidence interval (CI) 1.03-1.20]), to be prescribed (aPR 1.47 [95% CI 1.08-2.01]), and to take oral antivirals at any time (aPR 1.61 [95% CI 1.16-2.24]) or within 5&#xa0;days of infection (aPR 1.72 [95% CI 1.23-2.40]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite widespread awareness of the availability of COVID-19 oral antivirals, more than 80% of eligible US adults did not receive them. Our findings suggest that differences between perceived and actual risk for severe COVID-19 (based on current CDC guidelines) may partially explain this low uptake.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Penrose</LastName><ForeName>Kate</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7808-7439</Identifier><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), 55 W. 125 Street, 6 Floor, New York, NY, 10027, USA. kate.penrose@sph.cuny.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Avantika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), 55 W. 125 Street, 6 Floor, New York, NY, 10027, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yanhan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), 55 W. 125 Street, 6 Floor, New York, NY, 10027, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>McKaylee M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), 55 W. 125 Street, 6 Floor, New York, NY, 10027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulkarni</LastName><ForeName>Sarah G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), 55 W. 125 Street, 6 Floor, New York, NY, 10027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Kristen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puzniak</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nash</LastName><ForeName>Denis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), 55 W. 125 Street, 6 Floor, New York, NY, 10027, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Dis Ther</MedlineTA><NlmUniqueID>101634499</NlmUniqueID><ISSNLinking>2193-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Oral antiviral use</Keyword><Keyword MajorTopicYN="N">Perceived risk</Keyword></KeywordList><CoiStatement>Kristen E. Allen, Thomas M. Porter, Laura Puzniak and John M. McLaughlin are employees of Pfizer Inc. and hold stock and/or stock options of Pfizer Inc. Denis Nash discloses consulting fees from AbbVie and Gilead, and a research grant from Pfizer paid to his institution. Kate Penrose, Avantika Srivastava, Yanhan Shen, McKaylee M. Robertson, and Sarah G. Kulkarni report support from Pfizer through a research grant paid to their institution.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>23</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>23</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>23</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38909338</ArticleId><ArticleId IdType="pmc">PMC11266331</ArticleId><ArticleId IdType="doi">10.1007/s40121-024-01003-3</ArticleId><ArticleId IdType="pii">10.1007/s40121-024-01003-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rahmani K, Shavaleh R, Forouhi M, Disfani HF, Kamandi M, Oskooi RK, et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: a systematic review and meta-analysis. Front Public Health. 2022;26(10): 873596.10.3389/fpubh.2022.873596</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.873596</ArticleId><ArticleId IdType="pmc">PMC9459165</ArticleId><ArticleId IdType="pubmed">36091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Office of the Commissioner. U.S. Food and Drug Administration. FDA. Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19</Citation></Reference><Reference><Citation>Office of the Commissioner. U.S. Food and Drug Administration. FDA. Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain</Citation></Reference><Reference><Citation>Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509&#x2013;20. 10.1056/NEJMoa2116044</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397&#x2013;408. 10.1056/NEJMoa2118542</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, et al. Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge. N Engl J Med. 2022;387(9):790&#x2013;8. 10.1056/NEJMoa2204919</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204919</ArticleId><ArticleId IdType="pmc">PMC9454652</ArticleId><ArticleId IdType="pubmed">36001529</ArticleId></ArticleIdList></Reference><Reference><Citation>Dryden-Peterson S, Kim A, Kim AY, Caniglia EC, Lennes IT, Patel R, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. health system: a population-based cohort study. Ann Intern Med. 2023;176(1):77&#x2013;84. 10.7326/M22-2141</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-2141</ArticleId><ArticleId IdType="pmc">PMC9753458</ArticleId><ArticleId IdType="pubmed">36508742</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrakis V, Rafailidis P, Trypsianis G, Papazoglou D, Panagopoulos P. The antiviral effect of nirmatrelvir/ritonavir during COVID-19 pandemic real-world data. Viruses. 2023. 10.3390/v15040976. 10.3390/v15040976</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15040976</ArticleId><ArticleId IdType="pmc">PMC10144059</ArticleId><ArticleId IdType="pubmed">37112956</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. 2023;76(3):e342&#x2013;9. 10.1093/cid/ciac443</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac443</ArticleId><ArticleId IdType="pmc">PMC9214014</ArticleId><ArticleId IdType="pubmed">35653428</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganatra S, Dani SS, Ahmad J, Kumar A, Shah J, Abraham GM, et al. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019. Clin Infect Dis. 2023;76(4):563&#x2013;72. 10.1093/cid/ciac673</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac673</ArticleId><ArticleId IdType="pmc">PMC9452095</ArticleId><ArticleId IdType="pubmed">35986628</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah MM, Joyce B, Plumb ID, Sahakian S, Feldstein LR, Barkley E, et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19&#x2014;United States, April&#x2013;September 2022. Am J Transplant. 2023;23(1):150&#x2013;5. 10.1016/j.ajt.2022.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajt.2022.12.004</ArticleId><ArticleId IdType="pmc">PMC9833372</ArticleId><ArticleId IdType="pubmed">36695616</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023. 10.1016/S1473-3099(23)00011-7. 10.1016/S1473-3099(23)00011-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00011-7</ArticleId><ArticleId IdType="pmc">PMC10014040</ArticleId><ArticleId IdType="pubmed">36780912</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz KL, Wang J, Tadrous M, Langford BJ, Daneman N, Leung V, et al. Population-based evaluation of the effectiveness of nirmatrelvir-ritonavir for reducing hospital admissions and mortality from COVID-19. CMAJ. 2023;195(6):E220&#x2013;6. 10.1503/cmaj.221608</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.221608</ArticleId><ArticleId IdType="pmc">PMC9928441</ArticleId><ArticleId IdType="pubmed">36781188</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401(10373):281&#x2013;93. 10.1016/S0140-6736(22)02597-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02597-1</ArticleId><ArticleId IdType="pmc">PMC9779781</ArticleId><ArticleId IdType="pubmed">36566761</ArticleId></ArticleIdList></Reference><Reference><Citation>Gbinigie O, Ogburn E, Allen J, Dorward J, Dobson M, Madden TA, et al. Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease. BMJ Open. 2023;13(8): e069176. 10.1136/bmjopen-2022-069176</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-069176</ArticleId><ArticleId IdType="pmc">PMC10407406</ArticleId><ArticleId IdType="pubmed">37550022</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling WHK, Jittamala P, Watson JA, Boyd S, Luvira V, Siripoon T, et al. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. Lancet Infect Dis. 2023. 10.1016/S1473-3099(23)00493-0. 10.1016/S1473-3099(23)00493-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00493-0</ArticleId><ArticleId IdType="pmc">PMC7615401</ArticleId><ArticleId IdType="pubmed">37778363</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022;400(10359):1213&#x2013;22. 10.1016/S0140-6736(22)01586-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01586-0</ArticleId><ArticleId IdType="pmc">PMC9539539</ArticleId><ArticleId IdType="pubmed">36216007</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Al-Aly Z. Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records. BMJ. 2023;7(380): e072705.10.1136/bmj-2022-072705</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072705</ArticleId><ArticleId IdType="pmc">PMC9989554</ArticleId><ArticleId IdType="pubmed">36882199</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans A, Qi C, Adebayo JO, Underwood J, Coulson J, Bailey R, et al. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study. J Infect. 2023;86(4):352&#x2013;60. 10.1016/j.jinf.2023.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.02.012</ArticleId><ArticleId IdType="pmc">PMC9911979</ArticleId><ArticleId IdType="pubmed">36773891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DY, Abi Fadel F, Huang S, Milinovich AT, Sacha GL, Bartley P, et al. Nirmatrelvir or molnupiravir use and severe outcomes from omicron infections. JAMA Netw Open. 2023;6(9): e2335077. 10.1001/jamanetworkopen.2023.35077</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.35077</ArticleId><ArticleId IdType="pmc">PMC10514733</ArticleId><ArticleId IdType="pubmed">37733342</ArticleId></ArticleIdList></Reference><Reference><Citation>Paraskevis D, Gkova M, Mellou K, Gerolymatos G, Psalida &#x39d;, Gkolfinopoulou K, et al. Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in high-risk patients. J Infect Dis. 2023. 10.1093/infdis/jiad324. 10.1093/infdis/jiad324</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad324</ArticleId><ArticleId IdType="pmc">PMC10733724</ArticleId><ArticleId IdType="pubmed">37565522</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ. 2023;25(381): e074572.10.1136/bmj-2022-074572</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074572</ArticleId><ArticleId IdType="pmc">PMC10126525</ArticleId><ArticleId IdType="pubmed">37161995</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023. 10.1001/jamainternmed.2023.0743. 10.1001/jamainternmed.2023.0743</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>How Test to Treat Works for Individuals and Families. Available from: https://aspr.hhs.gov/TestToTreat/Pages/process.aspx</Citation></Reference><Reference><Citation>Smith ER, Oakley EM. Geospatial disparities in federal COVID-19 test-to-treat program. Am J Prev Med. 2023;64(5):761&#x2013;4. 10.1016/j.amepre.2023.01.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amepre.2023.01.022</ArticleId><ArticleId IdType="pmc">PMC9977692</ArticleId><ArticleId IdType="pubmed">37085247</ArticleId></ArticleIdList></Reference><Reference><Citation>Office of the Commissioner. U.S. Food and Drug Administration. FDA. Coronavirus (COVID-19) Update: FDA Authorizes Pharmacists to Prescribe Paxlovid with Certain Limitations. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pharmacists-prescribe-paxlovid-certain-limitations</Citation></Reference><Reference><Citation>Parkinson J. ContagionLive. 2023. FDA No Longer Requires Positive COVID-19 Test to Use 2 Antivirals. Available from: https://www.contagionlive.com/view/fda-no-longer-requires-positive-covid-19-test-to-use-2-antivirals</Citation></Reference><Reference><Citation>Levy ME, Burrows E, Chilunda V, Pawloski PA, Heaton PR, Grzymski J, et al. SARS-CoV-2 antiviral prescribing gaps among non-hospitalized high-risk adults. Clin Infect Dis. 2024. 10.1093/cid/ciad796. 10.1093/cid/ciad796</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad796</ArticleId><ArticleId IdType="pubmed">38170452</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma KC, Shirk P, Lambrou AS, Hassell N, Zheng XY, Payne AB, et al. Genomic surveillance for SARS-CoV-2 variants: circulation of omicron lineages&#x2014;United States, January 2022&#x2013;May 2023. MMWR Morb Mortal Wkly Rep. 2023;72(24):651&#x2013;6. 10.15585/mmwr.mm7224a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7224a2</ArticleId><ArticleId IdType="pmc">PMC10328465</ArticleId><ArticleId IdType="pubmed">37319011</ArticleId></ArticleIdList></Reference><Reference><Citation>Ipsos. Be Sure with KnowledgePanel&#xae;. 2018. Available from: https://www.ipsos.com/sites/default/files/18-11-53_Overview_v3.pdf</Citation></Reference><Reference><Citation>US Census Bureau. Current Population Survey Datasets [Internet]. [cited 2023 Jun 1]. Available from: https://www.census.gov/programs-surveys/cps/data/datasets.html</Citation></Reference><Reference><Citation>US Census Bureau. Data Releases. Available from: https://www.census.gov/programs-surveys/acs/news/data-releases.2021.html#list-tab-1133175109</Citation></Reference><Reference><Citation>Bradley VC, Kuriwaki S, Isakov M, Sejdinovic D, Meng XL, Flaxman S. Unrepresentative big surveys significantly overestimated US vaccine uptake. Nature. 2021;600(7890):695&#x2013;700. 10.1038/s41586-021-04198-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04198-4</ArticleId><ArticleId IdType="pmc">PMC8653636</ArticleId><ArticleId IdType="pubmed">34880504</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Centers for Disease Control and Prevention. 2023 [cited 2023 Jun 1]. People with Certain Medical Conditions. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html</Citation></Reference><Reference><Citation>Qasmieh SA, Robertson MM, Teasdale CA, Kulkarni SG, Jones HE, McNairy M, et al. The prevalence of SARS-CoV-2 infection and long COVID in U.S. adults during the BA.4/BA.5 surge, June-July 2022. Prev Med. 2023;169: 107461. 10.1016/j.ypmed.2023.107461</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2023.107461</ArticleId><ArticleId IdType="pmc">PMC9940463</ArticleId><ArticleId IdType="pubmed">36813250</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson MM, Qasmieh SA, Kulkarni SG, Teasdale CA, Jones H, McNairy M, et al. The epidemiology of long COVID in US adults. Clin Infect Dis. 2022. 10.1093/cid/ciac961. 10.1093/cid/ciac961</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac961</ArticleId><ArticleId IdType="pubmed">36542514</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus (COVID-19) Infection Survey: methods and further information. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/covid19infectionsurveypilotmethodsandfurtherinformation</Citation></Reference><Reference><Citation>COVID-19 Treatment Guidelines. Ritonavir-Boosted Nirmatrelvir (Paxlovid). Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/</Citation></Reference><Reference><Citation>Yan L, Streja E, Li Y, Rajeevan N, Rowneki M, Berry K, et al. Anti-SARS-CoV-2 pharmacotherapies among nonhospitalized US veterans, January 2022 to January 2023. JAMA Netw Open. 2023;6(8): e2331249. 10.1001/jamanetworkopen.2023.31249</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.31249</ArticleId><ArticleId IdType="pmc">PMC10472184</ArticleId><ArticleId IdType="pubmed">37651140</ArticleId></ArticleIdList></Reference><Reference><Citation>McGarry BE, Sommers BD, Wilcock AD, Grabowski DC, Barnett ML. Monoclonal antibody and oral antiviral treatment of SARS-CoV-2 infection in US nursing homes. JAMA. 2023. 10.1001/jama.2023.12945. 10.1001/jama.2023.12945</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.12945</ArticleId><ArticleId IdType="pmc">PMC10349351</ArticleId><ArticleId IdType="pubmed">37450293</ArticleId></ArticleIdList></Reference><Reference><Citation>Monach PA, Anand ST, Fillmore NR, La J, Branch-Elliman W. Underuse of antiviral drugs to prevent progression to severe COVID-19&#x2014;Veterans Health Administration, March&#x2013;September 2022. MMWR Morb Mortal Wkly Rep. 2024;73(3):57&#x2013;61. 10.15585/mmwr.mm7303a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7303a2</ArticleId><ArticleId IdType="pmc">PMC10824546</ArticleId><ArticleId IdType="pubmed">38271286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N, Klausner JD. Usage and awareness of antiviral medications for coronavirus disease 2019 (COVID-19) among individuals at risk for severe COVID-19, March 2021 to 1 August 2022. Clin Infect Dis. 2023;76(4):775&#x2013;6. 10.1093/cid/ciac743</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac743</ArticleId><ArticleId IdType="pubmed">36069403</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipolletta S, Andreghetti GR, Mioni G. Risk perception towards COVID-19: a systematic review and qualitative synthesis. Int J Environ Res Public Health. 2022. 10.3390/ijerph19084649. 10.3390/ijerph19084649</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19084649</ArticleId><ArticleId IdType="pmc">PMC9028425</ArticleId><ArticleId IdType="pubmed">35457521</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Liu RW, Foerster TA. Predicting intentions to practice COVID-19 preventative behaviors in the United States: a test of the risk perception attitude framework and the theory of normative social behavior. J Health Psychol. 2022;27(12):2744&#x2013;62. 10.1177/13591053211057382</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13591053211057382</ArticleId><ArticleId IdType="pubmed">34933582</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivy Oyegun E, Ategbole M, Jorgensen C, Fisher A, Hagen MB, Gutekunst L, et al. Factors associated with knowledge, attitudes, and behaviors regarding antiviral medications for COVID-19 among US adults. medRxiv. 2024. 10.1101/2023.12.11.23299148v2.abstract.10.1101/2023.12.11.23299148v2.abstract</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.12.11.23299148v2.abstract</ArticleId></ArticleIdList></Reference><Reference><Citation>Benchimol-Elkaim B, Dryden-Peterson S, Miller DR, Koh HK, Geller AC. Oral antiviral therapy utilization among adults with recent COVID-19 in the United States. J Gen Intern Med. 2023;38(7):1717&#x2013;21. 10.1007/s11606-023-08106-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-023-08106-6</ArticleId><ArticleId IdType="pmc">PMC9973233</ArticleId><ArticleId IdType="pubmed">36853557</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson M, Olson SM, Self WH, Ginde AA, Mohr NM, Gaglani M, et al. Ascertainment of vaccination status by self-report versus source documentation: impact on measuring COVID-19 vaccine effectiveness. Influenza Other Respi Viruses. 2022;16(6):1101&#x2013;11.10.1111/irv.13023</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13023</ArticleId><ArticleId IdType="pmc">PMC9350035</ArticleId><ArticleId IdType="pubmed">35818721</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjaden AH, Fette LM, Edelstein SL, Gibbs M, Hinkelman AN, Runyon M, et al. Self-reported SARS-CoV-2 vaccination is consistent with electronic health record data among the COVID-19 community research partnership. Vaccines (Basel). 2022. 10.3390/vaccines10071016. 10.3390/vaccines10071016</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10071016</ArticleId><ArticleId IdType="pmc">PMC9316024</ArticleId><ArticleId IdType="pubmed">35891180</ArticleId></ArticleIdList></Reference><Reference><Citation>Archambault PM, Rosychuk RJ, Audet M, Bola R, Vatanpour S, Brooks SC, et al. Accuracy of self-reported COVID-19 vaccination status compared with a public health vaccination registry in Qu&#xe9;bec: observational diagnostic study. JMIR Public Health Surveill. 2023;16(9): e44465.10.2196/44465</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/44465</ArticleId><ArticleId IdType="pmc">PMC10278735</ArticleId><ArticleId IdType="pubmed">37327046</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie D, Wang J. Comparison of self-reports and biomedical measurements on hypertension and diabetes among older adults in China. BMC Public Health. 2020;20(1):1664. 10.1186/s12889-020-09770-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-020-09770-7</ArticleId><ArticleId IdType="pmc">PMC7648423</ArticleId><ArticleId IdType="pubmed">33160325</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabowski MK, Reynolds SJ, Kagaayi J, Gray RH, Clarke W, Chang LW, et al. The validity of self-reported antiretroviral use in persons living with HIV: a population-based study. AIDS. 2018;32(3):363&#x2013;9. 10.1097/QAD.0000000000001706</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000001706</ArticleId><ArticleId IdType="pmc">PMC6171354</ArticleId><ArticleId IdType="pubmed">29194115</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Medicare &amp; Medicaid Services. Introduction of Prescription Oral Antivirals for COVID-19 to the Commercial Market. 2024. Available from: https://www.cms.gov/files/document/commercialcovid19oralantiviralsmemorevised20240220final.pdf</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>